All In Biotech

NDA 204767 · Fresenius Kabi USA

Acetaminophen

Acetaminophen · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 28, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,695

325 Phase 3, 144 recruiting

FAERS reports

260,681

227,384 serious, 51,102 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: Risk of Medication Errors and Hepatotoxicity Take care when prescribing, preparing, and administering Acetaminophen Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that: the dose in milligrams (mg) and milliliters (mL) is not confused; the dosing is based on weight for patients under 50 kg; infusion pumps are properly programmed; and the total daily dose of acetaminophen from all sources does not exceed maximum daily limits. Acetaminophen Injection contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the maximum daily limits, and often involve more than one acetaminophen-containing product [see Warnings and Precautions...

What it is approved for

From the label in effect Apr 24, 2024.

Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older the reduction of fever in adult and pediatric patients 2 years and older. Acetaminophen Injection is indicated for the Management of mild to moderate pain in adult and pediatric patients 2 years and older ( 1 ) Management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older ( 1 ) Reduction of fever in adult and pediatric patients 2 years and older ( 1 )

Mechanism: The precise mechanism of the analgesic and antipyretic properties of acetaminophen is not established but is thought to primarily involve central actions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 28, 2015 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • ACETAMINOPHEN · ACETAMINOPHEN 1GM/100ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.

All 1,695 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use23,638
  • fatigue21,350
  • drug ineffective19,003
  • pain18,796
  • nausea18,643
  • headache17,524
  • toxicity to various agents16,809
  • dyspnoea15,387
  • vomiting14,858
  • pyrexia14,826
  • arthralgia14,756
  • diarrhoea14,066

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,587
20052,685
20063,149
20072,550
20083,854
20092,962
20103,783
20118,055
20128,038
20133,367
20144,018
20156,103
20168,292
20177,458
20189,197
201912,626
202019,798
202120,049
202227,207
202327,954
202428,656
202528,267
202620,015

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Acetaminophen (Acetaminophen)

2024 spending

$126K

Beneficiaries

305

734 claims

Per beneficiary

$413

$0.20 per unit

View as table
YearSpending
2020$0
2021$35,877
2022$59,928
2023$48,943
2024$125,891

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,612 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.